Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Delhi High Court Bars...

    Delhi High Court Bars Cipla From Selling Novartis Respiratory Drug

    Written by supriya kashyap kashyap Published On 2017-03-11T10:08:57+05:30  |  Updated On 11 March 2017 10:08 AM IST
    Delhi High Court Bars Cipla From Selling Novartis Respiratory Drug
    New Delhi : The Delhi High Court barred Cipla Ltd. from manufacturing and selling a generic version of Swiss drug maker Novartis AG’s respiratory drug Onbrez in India.







    In doing so, the 2-judge bench of justices Badar Durrez Ahmed and Sanjeev Sachdev upheld an earlier order of the high court in January 2015 that restrained Cipla from making and selling Indacaterol the generic name of Onbrez until Cipla got compulsory licence for it.


    Cipla challenged the order before the 2-judge bench, saying permission to make and sell the drug was in larger public interest as Novartis’ drug was too expensive and made available only to government hospitals because of which is was not easily available to the public.


    Responding to the plea, the Delhi High Court said, “We do not feel that the appellant has even made out a case that public service would be disserved by the grant of an injunction. On the other hand, the respondents have established a prima facie case in that that patent is valid and, therefore, there is no credible challenge to the validity of the patent,” the bench said.


    In 2014, Cipla launched Indacaterol under its own brand name at one-fifth of the original price. Novartis, which held the patent for the drug, moved the high court for infringement, saying it had partnered with Cipla’s Indian rival Lupin Ltd. to sell the drug in India.


    The judges said they could not arrive at a definite conclusion on whether “the extent of imports is not sufficient for meeting the demands of chronic obstructive pulmonary disease (COPD) patients in India”.


    There are drugs available in the Indian market, besides Indacaterol, which deal with the management of COPD, the bench pointed out.


    Noting that Indacaterol does not fall in the category of a life saving drug, such as a cancer medicine, the bench in its 27-page judgement declined Cipla's contention that public interest may be a factor in considering the grant of an injunction.








    Badar Durrez AhmedChronic Obstructive Pulmonary DiseaseCOPDDelhi high courtNovartisOnbrezrespiratory drugSanjeev Sachdev
    Source : Bloomberg

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok